6-K 1 s-22_21580.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6 – K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2020

Commission File Number 0-31691

ZIM CORPORATION

150 Isabella Street, Suite 150

Ottawa, Ontario

Canada K1S 1V7

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Quarterly Business Review by Management for the

Quarter Ended June 30, 2020

TABLE OF CONTENTS

Item 1.	Selected Financial Data	3

Item 2.	Quarterly Business Review	7

Item 3.	Quantitative and Qualitative Disclosures About Market Risks	12

Signatures		14

ITEM 1 – SELECTED FINANCIAL DATA

ZIM Corporation
Condensed Consolidated Balance Sheets
(Expressed in US dollars, except for share data)

	June 30,
	2019			March 31,
	(Unaudited)			2020
ASSETS	$			$
Current assets
Cash and cash equivalents		247,835			429,824
Accounts receivable, net		196,655			25,513
Investment tax credits receivable Other tax credits		122,872 —			128,718 30,525
Prepaid expenses		22,722			29,190
		590,084			643,770

Investment		699,071			670,822
Right of uses assets		25,835			1,932
Property and equipment, net		6,787			17,225
		1,321,777			1,333,749
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable		52,962			13,601
Current lease liabilities		25,835			2,084
Accrued liabilities		14,323			26,308
Contract liabilities		—			57,862
Total liabilities		93,120			99,855

Shareholders' equity:
Preferred shares, no par value, non-cumulative		—			—
dividend at a rate to be determined by the Board of Directors redeemable for CDN $1 per share. Unlimited authorized shares; issued and outstanding NIL shares at June 30, 2020 and March 31, 2020.
Special shares, no par value, non-voting,
Unlimited authorized shares; issued and outstanding NIL shares at June 30, 2020 and March 31, 2020.		—			—
Common shares, no par value, voting,
Unlimited authorized shares; 8,136,348 shares issued and outstanding as at June 30, 2020 and 8,136,348 as at March 31, 2020.		19,491,842			19,491,842
Additional paid-in capital		2,966,068			2,966,068
Accumulated deficit		(21,042,724	)		(20,631,105	)
Accumulated other comprehensive income		(187,069	)		(592,812	)
		1,228,657			1,233,894
		1,321,777			1,333,749

ZIM Corporation
Condensed Consolidated Statements of Operations
(Expressed in US dollars)
(Unaudited)

	Three months ended June 30, 2020			Three months ended June 30, 2019
	$			$
Revenue from continuing operations
Mobile		11,539			24,877
Total revenue		11,539			24,877

Operating expenses from continuing operations
Cost of revenue		—			330
Selling, general and administrative		92,448			101,633
Research and development (net of tax credits)		5,416			4,233
Total operating expenses		97,864			106,196
Loss from continuing operations		(86,325	)		(81,319	)
Other income (expense):
Loss on disposition of assets		(258,492	)		—
Other expense		(607	)		—
Interest income , net		29			3,758
Total other income (expense)		(259,070	)		3,758
Net income (loss) from continuing operations		(345,395	)		(77,561	)

Discontinued operations
Revenue		—			63,937
Cost of revenue		—			(4,482	)
Selling, general and administrative		(57,075	)		(57,471	)
Research and development (net of tax credits)		(9,149	)		(29,371	)
Net income (loss) from discontinued operations		(66,224	)		(27,387	)
Net income (loss)		(411,619	)		(104,948	)
Basic and fully diluted income (loss) per share		(0.050	)		(0.013	)
Weighted average number of shares outstanding		8,136,348			8,136,348

ZIM Corporation
Condensed Consolidated Statements of Cash Flows
(Expressed in US dollars)
(Unaudited)

	Three months ended June 30, 2020			Three months ended June 30, 2019
	$			$
OPERATING ACTIVITIES
Net income (loss)		(411,619	)		(104,948	)
Items not involving operating cash:
Depreciation of property and equipment		702			2,104
Loss from sale of assets		258,492			—
Changes in operating working capital
Decrease (increase) in accounts receivable		(171,287	)		30,598
Decrease (increase) in tax credits receivable		36,371			(23,608	)
Decrease in prepaid expenses		6,468			8,177
Increase in accounts payable		39,361			(8,138	)
Increase (decrease) in accrued liabilities		(11,985	)		(7,304	)
Increase (decrease) in deferred revenue		(57,862	)		(10,432	)
Cash flows provided by operating activities		(311,359	)		(113,551	)
INVESTING ACTIVITIES
Purchase of property and equipment		—			—
Loss from sale of assets		(258,492	)		—
Cash flows provided by (used in) investing activities		(258,492	)		—
FINANCING ACTIVITIES
Cash flows provided by financing activities		—			—
Effect of changes in exchange rates on cash and cash equivalents		387,862			5,863
Increase (decrease) in cash		(181,989	)		(107,688	)
Cash and cash equivalents, beginning of period		429,824			506,524
Cash and cash equivalents, end of period		247,835			398,836

1 - BASIS OF PRESENTATION

The accompanying unaudited selected financial data of ZIM Corporation (“ZIM” or the “Company”) and its subsidiaries have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (US GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of June 30, 2020 has been derived from our audited consolidated financial statements for the year ended March 31, 2020. These selected financial data should be read in conjunction with the financial statements and notes thereto included in the latest annual report on Form 20-F. These data have been prepared on the same basis as the audited consolidated financial statements for the year ended March 31, 2020 and, in the opinion of management, include all adjustments considered necessary for a fair presentation of the financial position, results of operations and cash flows of the Company. Unless otherwise stated in this Form 6-K the information contained herein has not been audited or reviewed by an independent auditor. The results of operations for the three-month period ended June 30, 2020 are not necessarily indicative of the results to be expected for the full year.

- GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States ("US GAAP").The going concern basis of presentation assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. To date the Company has incurred an accumulated loss of $21,042,724 and cash flow used in operations of $311,359. This raises significant doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern and to realize the carrying value of its assets and discharge its liabilities and commitments when due is dependent on the Company generating revenue sufficient to fund its cash flow needs. There is no certainty that this and other strategies will be sufficient to permit the Company to continue as a going concern.

Management is currently investigating and evaluating options that may include recapitalization of the Company and pursuing other ventures of a different nature.

The consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis were not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets and liabilities, the reported revenue and expenses and the classifications used in the statement of financial position. Such differences in amounts could be material.

3 – INVESTMENT AND SUBSIDIARIES

Investments and long term deposits	Original Cost		Carrying Value		Available For Sale
Equispheres		112,752		688,655	No
Spiderwort		7,725		10,416	No

On August 24, 2018, NuvoBio Corporation made an investment in Spiderwort Inc. The investment consisted of the purchase of a $10,000 Canadian dollar ($7,725 US dollar) convertible promissory note and is accounted for at amortized cost. The note accrues simple interest of 5% per annum. On October 15, 2019, Spiderwort Inc. completed a qualifying equity financing in an amount greater than $3,000,000 Canadian dollars. NuvoBio automatically converted securities in Spiderwort to Class B voting common shares. The convertible promissory note converted into shares of Spiderwort at a value of $10,006 US dollars. This represents an unrealized gain on this equity investment of $2,956. Spiderwort Inc. is an advanced materials company developing novel, plant derived, biomaterial that will offer new avenues in 3D in vitro research and in regenerative medicine.

On June 5, 2020, ZIM Corporation announced the sale of its database technology business as part of management’s plan to focus the business on its biomedical subsidiary NuvoBio. The database assets include all of the Software, Consulting and Maintenance segment and have been purchased by members of Zim Corporation’s staff and will operate under the name Zim Databases Canada Inc. The purchase price of $84,584 ($120,000 Canadian dollars) is to be paid in 5 equal payments over a 5-year period on the anniversary date of the agreement. The sale resulted in a net loss of $258,492 due to the write down of intercompany amounts owing from ZIM do Brazil the effects of foreign exchange between Brazil and Canada.

ITEM 2 – QUARTERLY BUSINESS REVIEW

This Form 6-K contains forward-looking statements regarding our business, financial condition, results of operations, liquidity and sufficiency of cash reserves, recapitalization, restructuring, pursuit of new businesses, controls and procedures, prospects, revenue expectations, and allocation of resources that are based on our current expectations, estimates and projections. In addition, other written or oral statements which constitute forward-looking statements may be made by or on behalf of the registrant. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance, and are inherently subject to risks and uncertainties that are difficult to predict. As a result, actual outcomes and results may differ materially from the outcomes and results discussed in or anticipated by the forward-looking statements. These risks include foreign exchange risk, credit risk, fair value risks and key personnel risk and are therefore qualified in their entirety by reference to the factors specifically addressed in the sections entitled " QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK " and “RISK FACTORS” in our Annual Report on Form 20-F for the fiscal year ended March 31, 2020, as well as those discussed elsewhere in this Form 6-K. We operate in a very competitive and rapidly changing environment. New risks can arise and it is not possible for management to predict all such risks, nor can it assess the impact of all such risks on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. All forward-looking statements speak only as of the date of this Form 6-K. We undertake no obligation to revise or update publicly any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Form 6-K, other than as required by law.

The following discussion includes information from the Selected Financial Data for the three-month periods ended June 30, 2020 and 2019. These results are not necessarily indicative of results for any future period. You should not rely on them to predict our future performance.

All financial information is prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and is stated in US dollars.

EXECUTIVE SUMMARY

Revenue from continuing operations for the quarter ended June 30, 2020 was $11,539, a decline from $24,877 for the same period last year. The decrease in revenue resulted from decreased usage of our SMS routes.

Net loss for the quarter was $411,619, as compared to a net loss of $104,948 for the quarter ended June 30, 2019. The increase in losses is mainly due to the loss from the sales of the database business in the amount of $258,492 with the additional reduction in mobile segment revenue.

ZIM had cash and cash equivalents of $247,835 at June 30, 2020, as compared to cash and cash equivalents of $429,824 at March 31, 2020.

BUSINESS OVERVIEW

ZIM started operations as a developer and provider of database software known as ZIM IDE software. ZIM IDE software is used by companies in the design, development, and management of information databases and mission critical applications. On June 5, 2020, ZIM Corporation announced the sale of its database technology business as part of management’s plan to focus the business on its biomedical subsidiary NuvoBio. This operation was discontinued as of April 1, 2020.

Beginning in 2002, the Company expanded its business strategy to include opportunities associated with mobile products. Prior to fiscal 2007, the Company focused on developing products and services for the wireless data network infrastructure known as “SMS” or “text messaging”. SMS will continue to provide a minimal amount of revenue within the mobile segment of operations. With the acquisition of Advanced Internet Inc. (AIS) in 2007, the Company also offers mobile content directly to end users.

In 2017, our wholly-owned subsidiary, NuvoBio signed strategic partnerships and exclusive global licensing agreements with leading drug research institutes and companies. NuvoBio is currently funding research and development projects in the following areas:

	·	Implementing unique molecular interaction & analytics using supercomputing technologies to design small peptide drugs that bind to target proteins for cancer therapies; and

	·	The development of bi-specific immunology therapies for the treatment of kidney cancer.

CRITICAL ACCOUNTING ESTIMATES

We prepare our condensed consolidated financial statements in accordance with United States GAAP, which requires management to make certain estimates and apply judgments that affect reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On an ongoing basis, management reviews our accounting policies and how they are applied and disclosed in our annual consolidated financial statements.

There have been no material changes to our critical accounting estimates from those described in our Annual Report on Form 20-F for the fiscal year ended March 31, 2020.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2020 COMPARED TO THE THREE MONTHS ENDED JUNE 30, 2019

The following discussion includes information derived from the unaudited and not reviewed condensed consolidated statements of operations for the three months ended June 30, 2020 and 2019. The information for the three months ended June 30, 2020, in management's opinion, has been prepared on a basis consistent with the audited consolidated financial statements for the fiscal year ended March 31, 2020, and includes all adjustments necessary for a fair presentation of the information presented.

These operating results are not necessarily indicative of results for any future period. You should not rely on them to predict our future performance.

REVENUES

	Three months ended June 30, 2020		As a %		Three months ended June 30, 2019		As a %
		$				$
Bulk SMS		11,539		100		24,877		28
		11,539		100		24,877		28

Software (Discontinued)		—		—		3,187		4
Maintenance and consulting (Discontinued)		—		—		60,750		68
		—		—		63,937		72

Total Revenue		11,539		100		88,814		100

REVENUE ANALYSIS BY SERVICE/PRODUCT OFFERING

SOFTWARE, MAINTENANCE AND CONSULTING

Total revenues relating to the ZIM IDE have decreased from $63,937 to $NIL for the quarters ended June 30, 2019 and 2020, respectively. Due to the continuing decline in the software, maintenance and consulting line of business ZIM discontinued these operation in quarter one of fiscal year 2021. The database assets sold include all of the Software, Consulting and Maintenance segment and have been purchased by members of Zim Corporation’s staff and will continues these operations under the name Zim Databases Canada Inc.

BULK SMS

Bulk SMS messaging gives our customers the ability to send out a single message concurrently to a wide distribution list. Success in this industry is dependent on sending large quantities of messages on stable cost effective telecommunication routes. For the quarter ended June 30, 2020 we experienced a reduced volume of traffic from our customers using our routes and this resulted in comparable revenue of $11,539 to $24,877. In general, bulk messaging customers choose the service provider that is offering the lowest cost route. Different aggregators are able to negotiate different price points based on the traffic they are able to guarantee to the mobile operators. Due to the size of our competitors, and our competitors’ ability to negotiate better terms, there can be no guarantee that we will have routes that are the most cost effective in the future. We are not focusing on expanding this area of the business. As a result, we do not expect to see any further growth in our bulk messaging revenue during the remainder of fiscal 2021.

OPERATING EXPENSES

Continuing operations

	Three months ended June 30, 2020		Three months ended June 30, 2019		Period to period change
		$		$		$

Cost of revenue		—		330		(330	)
Selling, general and administrative		92,448		101,633		(9,185	)
Research and development		5,416		4,233		1,182
		97,864		106,196		(8,333	)

Discontinued operations

	Three months ended June 30, 2020		Three months ended June 30, 2019		Period to period change
		$		$		$

Cost of revenue		—		4,812		(4,812	)
Selling, general and administrative		57,075		57,471		(396	)
Research and development		9,149		29,371		(20,222	)
		66,224		91,324		(25,100	)

COST OF REVENUE

	Three months ended June 30, 2020			Three months ended June 30, 2019
		$			$
Mobile
Revenue		11,539			24,877
Cost of revenue		—			(330	)
Gross margin		11,539			24,547

Gross margin percentage		100	%		99	%

Discontinued operations
Revenue		—			63,937
Cost of revenue		—			(4,482	)
Gross margin		—			59,455

Gross margin percentage		0	%		93	%

SELLING, GENERAL AND ADMINISTRATIVE

Selling, general and administrative expenses related to continuiung operations for the quarters ended June 30, 2020 and June 30, 2019 were $92,448 and $101,633 respectively. The decrease in selling, general and administrative expense is mainly due to a reduction in rental expense and hosting fees.

Selling, general and administrative expenses related to discontinued operations for the quarters ended June 30, 2020 and June 30, 2019 were $57,075 and $57,471 respectively. The expenses in Q1 of fiscal 2021 are related to severance costs and management’s estimate of 60% of audit fees being related to discontinued operations.

STOCK-BASED COMPENSATION

For the three months ended June 30, 2020, and June 30, 2020, the Company recognized compensation expense for employees and consultants of NIL and NIL, respectively. The Company does not have any non-vested awards.

RESEARCH AND DEVELOPMENT

Research and development expenses related to continuiung operations for the quarters ended June 30, 2020 and 2019 were $5,416 and $4,233, respectively.

Research and development expenses related to discontinued operations for the quarters ended June 30, 2020 and 2019 were $9,149 and $29,371, respectively. The expenses in Q1 of fiscal 2021 are related to severance costs.

NET INCOME (LOSS)

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2020, ZIM had cash and cash equivalents of $247,835 and working capital of $497,109, as compared to cash and cash equivalents of $429,824 and working capital of $543,915 at March 31, 2020.

Cash flows for the fiscal periods were as follows:

	Three months ended June 30, 2020			Three months ended June 30, 2019
		$			$
Cash flows provided by operating activities		(311,359	)		(113,551	)
Cash flows provided by (used in) investing activities		—			—
Cash flows provided by financing activities		—			—

At June 30, 2019, the Company had a working capital line from its principal banker for approximately $36,689 in addition to a cash and cash equivalent balance of $247,835. Management believes that these funds, together with cash from on-going operations, may not be sufficient to fund existing operations for the next 12 months. Management is currently investigating and evaluating options that may include recapitalization of the Company, raising debt or equity capital and pursuing other ventures of a different nature.

Future liquidity and cash requirements will depend on a wide range of factors, including the level of success the Company has in executing its strategic plan as well as its ability to maintain business in existing operations and its ability to raise additional financing. If ZIM’s expenses surpass the funds available or if ZIM requires additional expenditures to grow the business, the Company may be unable to obtain the necessary funds and ZIM may have to curtail or suspend some or all of its business operations, which would likely have a material adverse effect on its business relationships, financial results, financial condition and prospects, as well as on the ability of shareholders to recover their investment.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements.

SUBSEQUENT EVENTS

None.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

FOREIGN EXCHANGE RISK

The Company operates internationally, giving rise to significant exposure to market risks from fluctuations and the degree of volatility of foreign exchange rates. The Company is exposed to exchange risk due to the following financial instruments denominated in foreign currencies.

Cash and cash equivalents includes the following amounts in their source currency:

	June 30, 2020		March 31, 2020

Canadian dollars		321,066		266,005
US dollars		12,242		6,638
Brazilian reals		—		1,223,708

Accounts receivable include the following amounts receivable in their source currency:

	June 30, 2020		March 31, 2020

Canadian dollars		147,423		17,349
US dollars		—		—
Brazilian reals		483,685		68,975

Accounts payable include the following amounts payable in their source currency:

	June 30, 2020		March 31, 2020

Canadian dollars		61,372		19,085
US dollars		7,929		—
Brazilian reals		—		772

Accrued liabilities include the following accruals in their source currency:

	June 30, 2020		March 31, 2020

Canadian dollars		15,163		32,012
US dollars		3,196		—
Brazilian reals		—		19,439

The Company does not use derivative financial instruments to reduce its foreign exchange risk exposure.

CREDIT RISK

The Company is exposed to credit-related losses in the event of non-performance by counterparties to financial instruments. Credit exposure is minimized by dealing with only creditworthy counterparties in accordance with established credit approval policies.

Concentration of credit risk in accounts receivable is indicated below by the percentage of the total balance receivable from customers in the specified geographic area:

	June 30, 2020			March 31, 2020

Canada		55	%		48	%
North America, excluding Canada		-%			-%
South America		45	%		52	%
		100	%		100	%

FAIR VALUE

The carrying values of cash and cash equivalents, accounts receivable, investment tax credits receivable, lines of credit, accounts payable and accrued liabilities approximate their fair value due to the relatively short periods to maturity of the instruments.

KEY PERSONNEL RISK

We currently depend heavily on the services of Dr. Michael Cowpland and Mr. James Stechyson. The loss of the services of Dr. Cowpland and Mr. Stechyson and other key personnel could affect our performance in a material and adverse way.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ZIM Corporation

Registrant

DATE

SIGNATURE

August 17, 2020

/s/ Dr. Michael Cowpland

Dr. Michael Cowpland, President and Chief Executive Officer

DATE

SIGNATURE

August 17, 2020

/s/ John Chapman

John Chapman, Chief Financial Officer